NCT05671432

The Study of CM326 in Moderate-to-severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of CM326 Injection in the Treatment of Adult Patients With Moderate-to-severe Atopic Dermatitis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Keymed Biosciences Co.Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.

Detailed description

The study consists of 3 periods, a up-to-4-week Screening Period, a 52-week Treatment Period and a 8-week Safety Follow-up Period.

Conditions

• Moderate-to-severe Atopic Dermatitis

Interventions

Type	Name	Description
BIOLOGICAL	CM326	CM326 injection
OTHER	Placebo	Placebo

Timeline

• Start date: 2022-12-27
• Primary completion: 2023-12-30
• Completion: 2024-12-30
• First posted: 2023-01-04
• Last updated: 2023-01-04

Locations

1 site across 1 country: China